Showing 5201-5210 of 5771 results for "".
- New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented ARVOhttps://modernod.com/news/new-scientific-and-clinical-analyses-regarding-bausch-lomb-surgical-and-pharmaceutical-products-to-be-presented-during-the-association-for-research-in-vision-and-ophthalmology-meeting/2476505/Bausch + Lomb announced that researchers will present the results of nine new scientific and clinical analyses involving the company’s pharmaceutical and surgical products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillanc
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- Allegro Expands Its Anti-Integrin Portfolio with New Dry Eye Disease Drug Candidate ALG-1007https://modernod.com/news/allegro-expands-its-anti-integrin-portfolio-with-new-dry-eye-disease-drug-candidate-alg-1007/2476499/Allegro Ophthalmics announced the expansion of the company’s anti-integrin portfolio with the new topical dry eye disease drug candidate ALG-1007. ALG-1007 bolsters Allegro’s existing anti-integrin portfolio, w
- Allergan to Showcase New Data at ARVOhttps://modernod.com/news/allergan-to-showcase-new-data-at-arvo/2476496/Allergan will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28 – May 2. Data will include three paper presentations on the company’s ophthalmology pipeline including
- Ziemer USA Sponsors NIIOS USA Cornea Eveninghttps://modernod.com/news/ziemer-usa-sponsors-niios-usa-cornea-evening-2/2476495/Ziemer USA is sponsoring the Netherlands Institute for Innovative Ocular Surgery (NIIOS) Cornea Evening in San Diego, California, on Friday, May 3, 2019, from 6-11 pm. For the third year in a row, NIIOS USA is organizing a Cornea Evening preceding the Annual Meeting of the American Society
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Akorn Receives FDA Approval for Generic Loteprednol Etabonatehttps://modernod.com/news/akorn-receives-fda-approval-for-generic-loteprednol-etabonate/2476485/Akorn announced that it received an abbreviated new drug application (NDA) approval from the FDA for loteprednol etabonate ophthalmic suspension, 0.5%. Loteprednol etabonate 0.5% is indicated for the treatment of postoperative inflammation following ocular surgery
- Bausch + Lomb to Initiate Series of US Clinical Trials for Technolas Teneo Excimer Laserhttps://modernod.com/news/bausch-lomb-to-initiate-series-of-us-clinical-trials-for-technolas-teneo-excimer-laser/2476482/Bausch + Lomb announced it will initiate a series of US clinical trials to evaluate the safety and efficacy of Technolas Teneo excimer laser for vision correction surgery for myopia and myopic astigmatism. The company expects the clinical trials to begin by July 2019. “The global LASIK mar
- Eric Bernabei Joins Avellino Labs as Chief Sales and Marketing Officerhttps://modernod.com/news/eric-bernabei-joins-avellino-labs-as-chief-sales-and-marketing-officer/2476483/Avellino Labs announced that Eric Bernabei has joined the company as chief sales and marketing officer. Mr. Bernabei, who brings more than 20 years of clinical and commercial ophthalmic experience to the role, will inform and implement the strategic expansion of Avellino Labs’ disruptive genetic
- LIGHTMED Appoints Lee Walker-Roberts as Global Business Development Directorhttps://modernod.com/news/lightmed-appoints-lee-walker-roberts-as-global-business-development-director/2476484/LIGHTMED announced the appointment of Lee Walker-Roberts as Global Business Development Director, effective immediately. Mr. Walker-Roberts is an experienced leader and executive advisor for high-tech companies ranging from privately-owned start-ups to companies with over $200 million in annual s